Ozmosi | AR-42 Drug Profile

Product Description

AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01129193)

Mechanisms of Action: HDAC6 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Alison Walker
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
OSU-15004	P1	Completed	Multiple Myeloma	2020-11-14	2021-06-16	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments\|Trial Status
14-078H	P1	Terminated	Meningioma\|Neurofibromatosis 2\|Neurilemmoma\|Neuroma, Acoustic\|Neurofibromatoses	2017-05-30	2022-05-12	Primary Endpoints
OSU-09102	P1	Completed	Mantle-Cell Lymphoma\|Testicular Cancer\|Intraocular Lymphoma\|Burkitt Lymphoma\|T-Cell Cutaneous Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|T-Cell Peripheral Lymphoma\|Prolymphocytic Leukemia\|Sezary Syndrome\|Prolymphocytic T-Cell Leukemia\|Mycosis Fungoides\|Adult T-Cell Leukemia-Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma\|B-Cell Marginal Zone Lymphoma\|Plasmablastic Lymphoma\|Leukemia, Plasma Cell\|Lymphoproliferative Disorders\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Immunoblastic Lymphadenopathy\|Large-Cell Immunoblastic Lymphoma\|Large-Cell Anaplastic Lymphoma\|Lymphomatoid Granulomatosis\|Multiple Myeloma\|Lymphocytic Chronic B-Cell Leukemia\|Extranodal NK-T-Cell Lymphoma\|Chronic Lymphoid Leukemia\|Lymphoma, Non-Hodgkin\|Waldenstrom Macroglobulinemia\|Prolymphocytic B-Cell Leukemia	2017-01-07	2019-03-19	Treatments
MCC-14-10774	P1	Terminated	Renal Cell Carcinoma\|Sarcoma\|Kidney Diseases	2016-11-24	2019-04-04	Patient Enrollment\|Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
OSU-11130	P1	Completed	Acute Myeloid Leukemia	2015-02-19	2019-03-19	Treatments

Recent News Events

Date	Type	Title
03/01/2024	PubMed	Lysosomal membrane proteins LAMP1 and LIMP2 are segregated in the Golgi apparatus independently of their clathrin adaptor binding motif.
12/19/2023	PubMed	Association Between Clinical Remission of Infantile-Onset Allergic Rhinitis During the School-Age Period and the Type of Housing: A Longitudinal Population-Based Japanese Study.
12/12/2023	PubMed	New Insights into the LANCL2-ABA Binding Mode towards the Evaluation of New LANCL Agonists.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

AR-42

Alternative Names: ar-42, ar42, ar 42 Clinical Status: Inactive Latest Update: 2024-03-01 Latest Update Note: PubMed Publication